Personalized cell therapy for recurrent medulloblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of personalized immune cells, vaccines, stem cells, and an immunotherapy drug (pembrolizumab) for children and young adults whose medulloblastoma has come back or grown. The goal is to help the immune system fight the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 4 and 30 years old.
- Your tumor must have come back or grown after standard treatment, and it must be a specific subtype (called Group 3 or Group 4).
- You must be able to have surgery or a biopsy, or have tumor tissue stored that can be used.
- You should be healthy enough for daily activities (performance score at least 60%).
- You must have adequate organ and blood function, such as normal kidney, liver, and heart function.
- You cannot be pregnant or breastfeeding, and must use contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune therapy using your child's own specially trained white blood cells to fight brain tumors. The treatment is given directly into the fluid around the brain, and it is for children with specific types of brain cancer.
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
This study tests a personalized treatment plan for children and young adults whose medulloblastoma or ependymoma has come back. It aims to guide doctors using new tissue from surgery or biopsy after earlier treatments are fully finished.
This trial tests a personalized immune cell therapy for adults with a specific type of brain tumor (oligodendroglioma) that has come back. The treatment uses your own immune cells to target the tumor.
This trial tests a new type of cell therapy called GPC2-CAR T cells for children and young adults whose medulloblastoma or related brain tumor has come back or not responded to standard treatment. The goal is to see if these specially designed immune cells can find and attack the tumor.
This trial tests a combination of antiangiogenic drugs (which block blood supply to tumors) for children with certain brain or spinal tumors that have returned or not responded to standard treatment. The goal is to see if this drug combo can shrink or slow the tumor.
Hear when a new Recurrent Group 3 Medulloblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.